Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer.
Although selective metabolic and receptor-based molecular agents will surely be included in the future of prostate cancer diagnosis and therapy, currently available inorganic compounds-such as18F-NaF for the diagnosis of bony disease and223RaCl2for the therapy of bone metastases-were recently shown to be superior to standard99mTc-phosphonates for diagnosis and153Sm-ethylenediaminetetramethylene phosphonate or89SrCl2for therapy. The advantages of18F-NaF include improved lesion detection and, when used in combination with CT, improved diagnostic confidence and specificity. In addition to being the first approved α-emitter,223RaCl2is the first radiopharmaceutical to show an increase in overall survival, a decrease in skeletal events, palliation of bone pain, and a low profile of adverse reactions (which are mild and manageable). The management of metastatic bone disease with223RaCl2is uniquely satisfying, as patients can be monitored directly during their monthly treatment visits.
Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California; and.
Andrei H
AH
Iagaru
Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California; and.
Erik
E
Mittra
Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, California.
Patrick M
PM
Colletti
Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, California jadvar@med.usc.edu.
Hossein
H
Jadvar
D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary* / Q000628:therapy*; D019317:Evidence-Based Medicine; D006801:Humans; D008297:Male; D057054:Molecular Imaging / Q000379:methods*; D058990:Molecular Targeted Therapy / Q000379:methods; D010166:Palliative Care / Q000379:methods; D049268:Positron-Emission Tomography / Q000379:methods*; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy; D011868:Radioisotopes / Q000627:therapeutic use*; D061089:Radiotherapy, Image-Guided / Q000379:methods; D016896:Treatment Outcome
D011868:Radioisotopes
PET; PET/CT; bone; cancer; prostate; radium
Curr Opin Urol. 2011 May;21(3):230-6
21378572
Expert Opin Investig Drugs. 2013 Mar;22(3):379-87
23316941
Acta Oncol. 2016;55(1):59-67
25833330
Cancer J. 2013 Jan-Feb;19(1):66-70
23337759
Eur J Cancer. 1991;27(9):1084-6
1720321
J Nucl Med. 2010 Dec;51(12 ):1826-9
21078790
Cancer. 2007 Feb 1;109 (3):637-43
17167764
Urol Oncol. 2014 Apr;32(3):252-60
24495450
Ann Oncol. 2008 Sep;19(9):1639-43
18467311
J Nucl Med. 2015 Oct;56(10 ):1507-12
26135112
Nuklearmedizin. 2009;48(1):37-43
19212610
Cancer Metastasis Rev. 2014 Sep;33(2-3):555-66
24452758
Cancer Manag Res. 2013;5:1-14
23326203
J Nucl Med. 2015 Jul;56(7):1119-29
25999432
Eur J Cancer. 2012 Mar;48(5):678-86
22341993
J Nucl Med. 2013 Feb;54(2):176-83
23243299
Nat Rev Urol. 2013 Sep;10(9):522-8
23797341
Adv Ther. 2013 Dec;30(12 ):1041-66
24276853
Semin Nucl Med. 1972 Jan;2(1):31-7
5059349
J Nucl Med. 1994 Jan;35(1):63-9
7505819
J Nucl Med. 2015 May;56(5):688-94
25840978
J Nucl Med. 2015 Sep;56(9):1304-9
26182965
Breast Care (Basel). 2012 Apr;7(2):100-107
22740795
J Natl Compr Canc Netw. 2012 Nov 1;10(11):1403-9
23138168
Cancer. 2015 Jan 1;121(1):69-76
25155428
J Nucl Med. 2015 Dec;56(12 ):1862-8
26405167
J Nucl Med. 1989 Nov;30(11):1814-8
2478681
Drugs R D. 2012 Dec 1;12(4):227-33
23190319
Lancet. 2001 Feb 3;357(9253):336-41
11210994
J Nucl Med. 2006 Feb;47(2):287-97
16455635
Semin Nucl Med. 2015 Jan;45(1):58-65
25475379
Clin Ter. 2009;160(3):193-9
19756320
J Nucl Med. 2005 Aug;46(8):1356-67
16085595
J Nucl Med. 1999 Oct;40(10 ):1623-9
10520701
J Nucl Med. 2009 Apr;50(4):501-5
19289439
Cancer Biother Radiopharm. 2015 Jun;30(5):195-9
25746633
Indian J Cancer. 2006 Apr-Jun;43(2):86-92
16790946
Clin Nucl Med. 2006 Oct;31(10 ):605-10
16985364
EJNMMI Res. 2011 Jun 07;1(1):4
22214491
Oncogene. 2014 Oct 23;33(43):5053-64
24276248
Health Phys. 2014 Apr;106(4):494-504
24562070
Ann Nucl Med. 2012 Jul;26(6):485-91
22477263
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):21-33
26266887
Clin Nucl Med. 2015 Feb;40(2):103-10
25290289
Q J Nucl Med. 2001 Mar;45(1):27-37
11456373
J Nucl Med. 2008 Jan;49(1):68-78
18077529
J Nucl Med. 1987 Apr;28(4):505-9
3572536
N Engl J Med. 2013 Jul 18;369(3):213-23
23863050
Eur Urol. 2013 Feb;63(2):189-97
23000088
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
26742998
J Nucl Med Technol. 2007 Jun;35(2):64-76; quiz 78-9
17496010
Clin Cancer Res. 2014 Jan 1;20(1):9-14
24190979
Clin Cancer Res. 2013 Nov 1;19(21):5822-7
24052017
Nucl Med Commun. 2007 Apr;28(4):245-50
17325585
J Clin Oncol. 1989 Dec;7(12 ):1926-31
2585026
Cancer Imaging. 2010 Jul 19;10 :1-8
20663736
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):8-20
26416392
J Nucl Med. 2015 Aug;56(8):1177-84
26069307